经典型PKC亚型对低氧诱导小鼠肺动脉平滑肌细胞增殖及ERK1/2、Akt表达的影响
该研究通过药物干预和病毒转染在体外探讨经典型PKC亚型对低氧诱导小鼠远端肺动脉平滑肌细胞增殖及ERK1/2、Akt磷酸化的影响。结果显示抑制cPKCα、βⅠ和βⅡ可显著抑制低氧诱导的细胞增殖并降低ERK1/2、Akt磷酸化水平,而PMA在常氧下促进增殖和磷酸化;敲减cPKCα、β可降低低氧下ERK1/2磷酸化但Akt无明显变化。结论提示低氧可能通过上调cPKCα、βⅠ和βⅡ蛋白表达经ERK1/2通路参与肺动脉平滑肌细胞异常增殖及低氧性肺动脉高压形成。
要点
- 抑制cPKCα、βⅠ或βⅡ可显著抑制低氧诱导的小鼠远端PASMC增殖。
- 抑制cPKCα、βⅠ或βⅡ可降低低氧诱导的PASMC中ERK1/2和Akt磷酸化水平。
- 敲减cPKCα、β可降低低氧下ERK1/2磷酸化,而Akt磷酸化无明显变化。
核心结论
- 低氧可能通过上调cPKCα、βⅠ和βⅡ蛋白表达使ERK1/2磷酸化水平增高,最终引起小鼠远端PASMC异常增殖,参与低氧性肺动脉高压形成。
- 调节cPKCα、βⅠ和βⅡ表达可能有助于减轻肺血管重塑,基于cPKCs的靶向治疗有望成为未来低氧性肺动脉高压治疗的新方向。
研究设计与样本
- 体外研究:利用Dynal MPC-1磁分离器分离含铁粉的远端肺小动脉,原代培养并鉴定小鼠肺动脉平滑肌细胞。
- 分别用PKC激动剂PMA、PKCα抑制剂safingol、PKCβⅠ抑制剂Go6976、PKCβⅡ抑制剂LY333531干预细胞,在常氧和低氧条件下用免疫印迹法观察cPKC亚型蛋白表达及ERK1/2、Akt磷酸化水平。
- 应用PKCα、PKCβ慢病毒载体通过病毒转染特异性敲减目标基因活性,用免疫印迹法观察低氧诱导小鼠PASMC中cPKC亚型蛋白表达及ERK1/2、Akt磷酸化水平。
主要发现
- Brdu法显示safingol、Go6976、LY333531分别抑制cPKCα、βⅠ和βⅡ时,低氧诱导的PASMC增殖受明显抑制,Brdu阳性细胞率分别为(7.35±0.26)% vs(11.28±0.43)%、(3.76±0.25)% vs(7.98±0.28)%和(4.12±0.46)% vs(7.78±0.53)%。
- PMA在常氧条件下可显著促进PASMC增殖,Brdu阳性细胞率分别为(9.65±0.47)% vs(6.34±0.52)%、(9.34±0.38)% vs(5.42±0.21)%和(7.78±0.53)% vs(4.12±0.46)%。
- PKCα、PKCβ慢病毒载体转染后,低氧转染组PASMC增殖能力较空载对照组显著下降,Brdu阳性细胞率为(3.58±0.54)% vs(5.97±0.63)%。
- safingol抑制后ERK1/2、Akt磷酸化水平分别为0.56±0.07 vs 1.08±0.13和0.49±0.04 vs 0.97±0.08;Go6976后分别为0.41±0.09 vs 0.79±0.10和0.48±0.09 vs 0.82±0.16;LY333531后分别为0.42±0.03 vs 0.87±0.06和0.34±0.07 vs 0.78±0.05。
- PMA可使常氧条件下PASMC中ERK1/2、Akt磷酸化水平增高,分别为1.25±0.12 vs 0.41±0.07和0.98±0.06 vs 0.37±0.08;低氧条件下转染敲减cPKCα、β后ERK1/2磷酸化水平显著降低(0.29±0.06 vs 0.76±0.05),Akt磷酸化水平无明显变化。
临床怎么用
- 本研究为体外细胞机制研究,提示cPKCα、βⅠ和βⅡ及ERK1/2、Akt通路可能参与低氧性肺动脉高压的肺血管重塑,尚不能直接转化为临床诊疗推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To study the effects of specific isoforms of classic protein kinase C (cPKCs) on hypoxia-induced proliferation and the expression of ERK1/2 and Akt using drug intervention or virus transfection in vitro. Methods: Dynal MPC-1 magnetic particle concentrator was used to separate iron-containing pulmonary arterioles fragments, and the pulmonary artery smooth muscle cells (PASMCs) were primary cultured and identified. The cells were intervened by PKC agonist (PMA), PKCα inhibitor (safingol), PKCβⅠ inhibitor (Go6976) and PKCβⅡ inhibitor (LY333531) respectively, and the changes in protein expressions of cPKCs, and the phosphorylation levels of ERK1/2 and Akt were observed by immunoblotting under the condition of normal oxygen or hypoxia. The lentiviral vectors of PKCα and PKCβ were used to specifically knock-down the activity of target genes by virus transfection techniques, and Western blotting was used to observe the protein expressions of cPKCs, and the phosphorylation levels of ERK1/2 and Akt in hypoxia-induced PASMCs in mice. Results: With Brdu method, the proliferation of PASMCs induced by hypoxia was significantly inhibited by safingol, Go6976 and LY333531 by inhibiting cPKCα, βⅠ and βⅡ respectively. Compared with the hypoxic control group, the rates of Brdu positive cells were (7.35±0.26)% vs (11.28±0.43)%, (3.76±0.25)% vs (7.98±0.28)% and (4.12±0.46)% vs (7.78±0.53)%. We also observed that PMA could significantly promote the proliferation of PASMCs under normoxic condition. Compared with the normoxia control group, the Brdu-positive cell rates were (9.65±0.47)% vs (6.34±0.52)%, (9.34±0.38)% vs (5.42±0.21)% and (7.78±0.53)% vs (4.12±0.46)%. In addition, after transfection with PKCα or PKCβ lentiviral vector, the proliferation of PASMCs was significantly lower in hypoxia transfection group than in the control group. The rates of Brdu positive cells were (3.58±0.54)% vs (5.97±0.63)%, respectively. Using Western blotting, we also observed that after being inhibited by safingol, Go6976 and LY333531 respectively, the phosphorylation levels of ERK1/2 and Akt in PASMCs induced by hypoxia was significantly lower than the control group. After using safingol, the phosphorylation levels of ERK1/2 and Akt were (0.56±0.07) vs (1.08±0.13) and (0.49±0.04) vs (0.97±0.08). After using Go6976, the phosphorylation levels of ERK1/2 and Akt were (0.41±0.09) vs (0.79±0.10) and (0.48±0.09) vs (0.82±0.16), after using LY333531, the phosphorylation levels of ERK1/2 and Akt were (0.42±0.03) vs (0.87±0.06) and (0.34±0.07) vs (0.78±0.05). While PMA could promote the phosphorylation levels of ERK1/2 and Akt under normoxic condition, 1.25±0.12 vs 0.41±0.07 and 0.98±0.06 vs 0.37±0.08, respectively. Using transfection technique to specifically knock down the expression of cPKCα and β, we found that under hypoxic conditions, transfection of PASMCs could significantly lower the phosphorylation levels of ERK1/2, its phosphorylation level was 0.29±0.06 vs 0.76±0.05, with no evident change in the phosphorylation levels of Akt. Conclusions: Hypoxia may lead to phosphorylation of ERK1/2 by promoting the protein expression of cPKCα, cPKCβⅠ and cPKCβⅡ respectively, which eventually induces abnormal proliferation of PASMCs from the distal pulmonary arteries, participating in the development of hypoxic pulmonary hypertension (HPH) of the mice. Regulation of the expression of cPKCα, cPKCβⅠ and cPKCβⅡ may help to attenuate the formation of pulmonary vascular remodeling. Target therapy based on cPKCs is expected to be a new direction for HPH therapy in the future. 目的: 探讨经典型蛋白激酶C(PKC)对低氧诱导的小鼠远端肺动脉平滑肌细胞(PASMC)增殖及细胞外信号调节激酶1/2(ERK1/2)、丝氨酸苏氨酸蛋白激酶(Akt)表达的影响。 方法: 利用Dynal MPC-1磁分离器分离含铁粉的远端肺小动脉,原代培养并鉴定肺动脉平滑肌细胞。应用PKC激动剂(PMA)、PKCα抑制剂(safingol)、PKCβⅠ抑制剂(Go6976)、PKCβⅡ抑制剂(LY333531)分别干预细胞。在常氧和低氧条件下,采用免疫印迹法观察cPKC亚型蛋白表达变化以及ERK1/2、Akt磷酸化水平变化。应用PKCα、PKCβ的慢病毒载体,通过病毒转染技术特异性敲减目标基因活性,采用免疫印迹法观察低氧诱导小鼠PASMC中cPKC亚型蛋白表达变化,以及ERK1/2、Akt磷酸化水平变化。 结果: 采用Brdu法,检测到用safingol、Go6976、LY333531分别抑制cPKCα、βⅠ和βⅡ时,低氧诱导的PASMC增殖能力受到明显抑制,与低氧对照组相比,Brdu阳性细胞率分别为(7.35±0.26)% vs(11.28±0.43)%,(3.76±0.25)% vs(7.98±0.28)%和(4.12±0.46)% vs(7.78±0.53)%;且PMA在常氧条件下可显著促进PASMC的增殖能力,与常氧对照组相比,Brdu阳性细胞率分别为(9.65±0.47)% vs(6.34±0.52)%,(9.34±0.38)% vs(5.42±0.21)%和(7.78±0.53)% vs(4.12±0.46)%;此外经过PKCα、PKCβ的慢病毒载体转染细胞后,也发现低氧转染组的PASMC增殖能力较空载对照组显著下降,Brdu阳性细胞率分别为(3.58±0.54)% vs(5.97±0.63)%。用safingol、Go6976、LY333531分别抑制cPKCα、βⅠ和βⅡ表达后,低氧诱导的PASMC中ERK1/2、Akt的磷酸化水平较对照组显著降低,使用safingol之后,ERK1/2、Akt的磷酸化水平分别为:0.56±0.07 vs 1.08±0.13和0.49±0.04 vs 0.97±0.08,使用Go6976之后,ERK1/2、Akt的磷酸化水平分别为:0.41±0.09 vs 0.79±0.10和0.48±0.09 vs 0.82±0.16,使用LY333531之后,ERK1/2、Akt的磷酸化水平分别为:0.42±0.03 vs 0.87±0.06和0.34±0.07 vs 0.78±0.05;PMA可使常氧条件下PASMC中ERK1/2、Akt的磷酸化水平增高,分别为1.25±0.12 vs 0.41±0.07和0.98±0.06 vs 0.37±0.08;利用病毒转染技术对cPKCα、β的表达进行特异性敲底,发现在低氧条件下,转染细胞后均可使细胞中ERK1/2磷酸化水平显著降低,其磷酸化水平为0.29±0.06 vs 0.76±0.05,而Akt磷酸化水平较对照组无明显变化。 结论: 激动剂及抑制剂干预或病毒转染可使PASMC中cPKCα、βⅠ和βⅡ表达下降,可显著抑制低氧诱导的小鼠远端PASMC异常增殖,其作用机制可能与cPKCα、βⅠ和βⅡ蛋白表达上调有关。低氧可能通过上调cPKCα、βⅠ和βⅡ的蛋白表达,使得ERK1/2磷酸化水平增高,最终引起小鼠远端PASMC的异常增殖,参与低氧性肺动脉高压的形成过程。.
引用
- Shi YW, Qin XJ, Zeng C, et al. [Effects of typical PKC subtypes on the proliferation of mouse pulmonary artery smooth muscle cells and the expression of ERK1/2 and Akt induced by hypoxia]. Zhonghua Jie He He Hu Xi Za Zhi. 2022. PMID: 35527461. doi:10.3760/cma.j.cn112147-20211022-00730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。